A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond and current biomarkers (eg, programmed death 1 ligand 1 [PD-L1]), mismatch repair deficiency [dMMR]/high microsatellite i...

Popoln opis

Bibliografske podrobnosti

Principais autores:	T. S. Ramasubramanian, Pichet Adstamongkonkul, Christina M. Scribano, Christin Johnson, Sean Caenepeel, Laura C.F. Hrycyniak, Lindsey C. Vedder, Nicholas Dana, Christian Baltes, Victoria Browning, Yuan-I Chen, Thomas Dietz, Evan Flietner, Nicholas Kaplewski, Anna Kellner, Michael Korrer, Chao Liu, Nathan Marhefke, Payton McDonnell, Amreen Nasreen, Victoria Pope, Abhijeet Prasad, Jordyn Richardson, Sidney Schneider, Mikaela M. Schultz, Chetan Sood, Aishwarya Sunil, Erika von Euw, Eric Wait, Ellen E. Wargowski, Pooja Advani, Barbara Broome, Antje Bruckbauer, Andrew Godwin, Nima Kokabi, Yanyan Lou, Robert C. G. Martin, Mercedes Robaina, Giuseppe Toia, Joshua Routh, Andreas Friedl, Kevin Eliceiri, Michael Szulczewski, Scott Johnson, Jon Oliner, Jérôme Galon, Christian Capitini, Debabrata Mukhopadhyay, Janis Taube, David Braun, Hinco J. Gierman
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-01-01
Serija:	Journal of Translational Medicine
Online dostop:	https://doi.org/10.1186/s12967-025-07378-2
Oznake:	Označite Brez oznak, prvi označite!